Terminological qualification is required when assigning the designation “veterinary grade API” to a multi-constituent botanical composite such as Bushen Zhuangyang Powder. Unlike a monomolecular API defined by a single chemical entity, a published purity specification, and a compendial monograph, this material comprises dried and milled plant fractions whose biological activity cannot be reduced to one active moiety. Quality control and pharmaceutical development therefore operate through marker compound standardization rather than single-analyte assay. Icariin, geniposidic acid, and hyperoside are among the analytical markers quantified by HPLC–DAD, with acceptance criteria typically expressed as mg/g of dried powder. Batch-to-batch variance in botanical raw materials remains the dominant source of downstream process variability, requiring formulators to calibrate granulation, compression, and dissolution parameters against each incoming lot rather than against a fixed, inert excipient matrix. Published data for this specific multi-herb configuration are fragmentary, but the unit operations described below are drawn from industrial practice with commensurate botanical drug substances.

When Does a Multi-Herb Powder Demand Wet Granulation Instead of Direct Compression?

The selection of wet granulation over direct compression for Bushen Zhuangyang Powder is governed not by API solubility but by particle size distribution, bulk density, and flowability of the botanical blend. Mill-comminuted herb powders commonly exhibit a fused, laminar particle morphology with poor flow characteristics and a Carr’s index frequently exceeding 30%, above the 25% threshold recommended for high-speed tablet press feeds. Direct compression at production speeds (≥ 60,000 tablets/h on rotary presses such as the Korsch XL 400 or Fette 3090i) produces unacceptable weight variability, typically exceeding ± 5% RSD against a compendial target of ± 3%. Wet granulation with a 5–7 wt% povidone K-30 aqueous binder solution in a fluid bed granulator (Glatt GPCG 5/10, inlet air temperature set at 55–60°C, product temperature maintained below 40°C to preserve heat-labile flavonoid glycosides) yields granulate with a target particle size fraction of 0.2–0.8 mm and a tapped density of 0.55–0.65 g/mL. Loss-on-drying prior to compaction is held between 1.5% w/w and 2.5% w/w; moisture below this range causes excessive capping due to low granule friability, while moisture above 3.0% increases sticking tendency on polished punch surfaces. The powder’s hygroscopic character, confirmed by dynamic vapour sorption isotherm testing (DVS Intrinsic, Surface Measurement Systems, with a mass increase of 8–12% at 60% RH and 25°C), requires tableting bays conditioned at ≤ 45% relative humidity and 20–22°C, with dehumidified hopper storage maintained when machine stoppages exceed 15 minutes. Magnesium stearate at 0.5–1.0 wt% as a lubricant (Blend-Trol, 3–5 minute mixing time) reduces ejection force to below 2,000 N; exceeding this level, or blending beyond 5 minutes, generates hydrophobic films on granule surfaces that retard tablet disintegration beyond the 15-minute acceptance window specified in USP Chapter <701> for immediate-release solid dosage forms.Dry granulation by roller compaction (Alexanderwerk WP 120 or Fitzpatrick chilsonator, roll surface speed 12–18 rpm, hydraulic pressure 60–80 bar) generates densified flakes that are milled through a ConiWitt sieve mill equipped with a 0.8–1.0 mm rasping screen and subsequently blended with 0.25–0.5 wt% colloidal silicon dioxide to enhance flow for high-speed capsule filling. The resulting granulate is characterized by a Freeman FT4 powder rheometer conditioned bulk density of 0.65–0.72 g/mL and a basic flowability energy of 180–220 mJ, parameters suitable for Bosch GKF 2600 capsule fillers operating at 4,500–6,000 capsules/h. Hard gelatin capsule shells (size 0 to size 2) are filled using a dosator pin system to achieve a fill weight variance of ≤ ± 4% RSD per station; mechanical stations deviating beyond ± 5% are excluded from lot assembly. The hygroscopic nature of the granulate dictates that empty capsule shells be pre-conditioned in a desiccated cabinet at 25°C and 35% RH for a minimum of 12 hours prior to filling, because capsules conditioned at > 55% RH develop plasticized shell walls that collapse during sorting and printing operations. Post-fill polish protocols employ a Sejong pharma centrifugal polishing machine operated at 180 rpm with a cloth residence time of 40–60 seconds per tray. Encapsulation trials with methylparaben-containing formulations indicate compatibility constraints: the preservative at concentrations above 0.18 wt% induces pinhole formation in gelatin shells over 6-month stability storage at 40°C / 75% RH, attributable to pH-mediated hydrolysis at the capsule interface. This defect pattern is consistent with documented gelatin shell degradation when exposed to low-molecular-weight parabens under accelerated ICH Q1A(R2) conditions.

Where Aqueous Suspension Vehicles Destabilize at Low pH, Buffer Selection Becomes Process-Defining

For oral solution and suspension presentations of Bushen Zhuangyang Powder, the primary process conflict is pH-dependent precipitation and flocculation of polyphenolic constituents. The botanical composite contains flavonoid glycosides, including icariin with a log P of approximately 1.4 and aqueous solubility below 0.5 mg/mL at pH 6.8, and tannin polymers that exhibit strong pH-dependent solubility profiles. Direct dissolution in purified water yields an unacceptable suspension that separates within 2 hours with a sediment ratio below 0.3. A suspension vehicle incorporating 0.1–0.3 wt% xanthan gum (Vanzan NF, 80 mesh) hydrated under high shear (Silverson L5M-A rotor–stator at 8,000 rpm for 5 minutes) produces a pseudoplastic rheological profile with a yield stress of 2–5 Pa and a plastic viscosity of 80–120 cP at 25°C, sufficient to maintain a redispersible suspension for a minimum of 30 days under accelerated storage at 40°C / 75% RH. Sodium carboxymethylcellulose at 2 wt% (degree of substitution 0.7–0.9) offers superior thermal stability but exhibits electrolyte sensitivity, undergoing viscosity collapse from approximately 150 cP to below 30 cP upon addition of 0.1 wt% potassium sorbate. Buffer selection is constrained by the denaturation window for flavonoid glycosides in acidic media: storage below pH 4.0 accelerates hydrolysis of the glycosidic linkage, reducing icariin recovery to 82% after 14 days at 40°C as verified by HPLC–DAD. Phosphate buffers at pH 6.0–6.5 (0.05 M, USP Chapter <1072>) maintain marker recoveries above 95% over 14 days, but phosphoric acid-buffered vehicles are incompatible with aluminum chloride-based tannin assays, necessitating a switch to a vanillin–sulfuric acid method for QC release testing. Methylparaben 0.18 wt% combined with propylparaben 0.02 wt% provides adequate preservation for multi-dose oral suspension packaging; sorption to xanthan gum reduces free methylparaben concentration by 15–20% within 72 hours, requiring an overage factor of 1.2. Accelerated stability testing per VICH GL17 (Scheme B for climatic zone IVb: 40°C ± 2°C / 75% ± 5% RH for 6 months) establishes that the oral suspension remains within specification for appearance, pH (± 0.3 units), microbial limits (total aerobic count ≤ 10² CFU/mL, total combined yeast and mold ≤ 10¹ CFU/mL, USP Chapter <61>), and antimicrobial preservative effectiveness (USP Chapter <51>) when stored in amber PET bottles at 25°C for 24 months.Feed premix incorporation of Bushen Zhuangyang Powder follows a stepwise geometric dilution protocol to ensure content uniformity in low-inclusion formulations. Target feed inclusion rates of 0.5–2.0 kg/tonne feed (equivalent to 0.05–0.2 wt% in finished feed) place the powder in the micro-ingredient category, where assay variability must be controlled to ± 10% of label claim according to common feed regulatory acceptance criteria. A secondary carrier pre-blend is prepared by combining the herbal powder with ground corncob grit (particle size 250–450 µm, moisture ≤ 9 wt%) in a 1:9 ratio using a horizontal ribbon mixer (Scott Equipment or comparable, ribbon-to-vessel clearance 5–8 mm) operated at 25–30 rpm for 8–10 minutes; coefficient of variation for the pre-blend is verified by sampling 10 random points and quantifying marker compound content by HPLC, with a CV target of ≤ 5% RSD. The pre-blend is then incorporated into the main feed mixer in a second dilution step, typically 1 part pre-blend to 99 parts base ration, with a mixing time of 4–6 minutes after addition measured from the point of complete discharge. Prolonged mixing beyond 12 minutes generates electrostatic separation of fine herbal particles from denser mineral components, creating pockets of sub-potent and hyper-potent distribution in the finished feed. Pelletization introduces a thermal stress step: conditioner set points of 75–85°C for 30–45 seconds (typical for swine and poultry mash-to-pellet conversion) reduce marker compound recoveries by 8–15% depending on the specific botanical constituent, with icariin showing the greatest thermal sensitivity among commonly assayed markers. Extrusion processing above 90°C should be avoided unless a 15–20% overage of the botanical powder is factored into the pre-blend formulation, a practice that carries its own regulatory complexity in markets where maximum residue limits for herbal markers have not been established. Published data for this specific thermal degradation profile across commercial extruder configurations is limited.

Injectable Compatibility Boundaries for a Non-Sterile Botanical Feedstock

The translation of Bushen Zhuangyang Powder into an injectable presentation confronts the most severe technical boundary conditions of any dosage route discussed. A milled botanical composite cannot be rendered injectable by simple sterile filtration (0.22 µm PVDF membrane) because the constituent particles in a powder presentation are orders of magnitude larger than the membrane pore size; a 0.22 µm filter removes essentially all suspended particulate matter, including the entire marker compound population. Preparation of an injectable solution therefore requires exhaustive solvent extraction, clarification, and concentration steps that fundamentally alter the compositional fingerprint of the starting material. A representative sequence involves reflux extraction in 70% ethanol–water (v/v) at 80°C for 2 hours, filtration through a 0.45 µm pre-filter, rotary evaporation under reduced pressure (Heidolph Hei-VAP, 60–65°C water bath, 120 mbar), and reconstitution in Water for Injection (EP grade) to a controlled marker concentration, for example icariin normalized to 0.5 mg/mL. The resulting solution, before terminal sterilization, must pass bacterial endotoxin limit testing (USP Chapter <85>, threshold not exceeding 0.5 EU/mg of dried extract) and particulate matter counts (USP Chapter <788>, no more than 25 particles ≥ 10 µm and no more than 3 particles ≥ 25 µm per mL). Terminal sterilization by autoclaving at 121°C for 15 minutes has been evaluated in limited stability studies; post-autoclave marker recovery is approximately 85–92%, with icariin showing the greatest degradation among commonly assayed compounds. Sterility assurance for such preparations is usually achieved through aseptic processing rather than terminal sterilization directly on the reconstituted solution, because autoclave denaturation of heat-labile flavonoid glycosides exceeds acceptable degradation thresholds in some batches, an operational uncertainty attributable to batch-to-batch variance in the relative percentage of individual botanical constituents. Published pharmacokinetic data for such injectable preparations in food-producing animals is limited, and regulatory pathways for injectable multi-herb botanical preparations are not harmonized across EMA, FDA-CVM, or the Chinese Veterinary Pharmacopoeia, meaning that each export market requires a separate regulatory dossier with in-country stability data and analytical method transfer evidence.Granule-based delivery forms of Bushen Zhuangyang Powder are prepared through a low-moisture extrusion–spheronization route that avoids the high-temperature drying cycles associated with fluid-bed granulation. A binder solution of 5 wt% hypromellose (Pharmacoat 606, methoxy content 28–30%, hydroxypropoxy content 7–12%) in purified water is blended with the botanical powder in a planetary mixer (40 rpm bowl speed, 12 minutes) until the wet mass attains a consistency that passes the manual compression test. Extrusion is performed through a Fuji Paudal twin-dome extruder with a 0.8 mm die plate at a screw speed of 30 rpm; the extrudates are then spheronized on a Caleva MBS 120 spheronizer equipped with a cross-hatched plate rotating at 900–1,200 rpm for 3–5 minutes, yielding near-spherical pellets with an aspect ratio of 1.0–1.2. The pellets are dried in a tray dryer at 45°C for 4–6 hours to achieve a moisture content of 2.0–3.0 wt% (Mettler Toledo HE53 halogen moisture analyzer) and then screened through a 1.0 mm sieve to remove fines. Direct oral granules intended for dosing via volumetric equipment require a bulk density of 0.45–0.55 g/mL and a tapped density not exceeding 0.70 g/mL to ensure flow through automatic fill auger systems calibrated to deliver 2.0–5.0 g per unit dose. Dissolution testing of the granule form under simulated gastric fluid (0.1 M HCl, pH 1.2, USP Apparatus II, 50 rpm, 37°C) shows that marker compound release reaches 80% within 30–45 minutes, although batch-to-batch botanical variation shifts this window by ± 10 minutes. Shelf-life assignment for granule presentations stored in aluminum foil laminate pouches (moisture vapour transmission rate < 0.01 g/m²/24 h) at 25°C / 60% RH is conservatively set at 24 months, with periodic marker compound re-assay scheduled every 6 months for lots retained under ICH Q1A(R2) long-term stability protocols.No single monograph in USP, EP, or the Chinese Veterinary Pharmacopoeia provides a consolidated specification for Bushen Zhuangyang Powder as a veterinary grade API. Release testing for the powder as received from the manufacturer therefore assembles requirements from multiple compendial chapters and annexes, summarized in the following matrix.

Test Parameter	Standard / Method Designation	Typical Acceptance Criteria
Identification of marker compounds	HPLC–DAD; ChP 2020 General Chapter 0512	Icariin ≥ 2.0 mg/g; geniposidic acid ≥ 0.5 mg/g
Total ash	ChP 2020 General Chapter 2302	≤ 8.0 wt%
Acid-insoluble ash	ChP 2020 General Chapter 2302	≤ 2.0 wt%
Heavy metals	USP Chapter <261> / ICP–MS	Pb ≤ 5 ppm; As ≤ 2 ppm; Cd ≤ 1 ppm; Hg ≤ 0.1 ppm
Loss on drying	USP Chapter <731>; 105°C, 5 h	≤ 12 wt%
Particle size distribution	Laser diffraction (Malvern Mastersizer)	D90 ≤ 150 µm
Microbial limits	USP Chapter <61> / <62>	TAMC ≤ 10⁴ CFU/g; TYMC ≤ 10² CFU/g; E. coli absent; Salmonella absent
Residual pesticides	ChP 2020 General Chapter 2341 / USP Chapter <561>	BHC ≤ 0.2 mg/kg; DDT ≤ 0.2 mg/kg; PCNB ≤ 0.1 mg/kg